

## **Supplementary Figure 1**

Bevacizumab reduces the growth rate constants of renal carcinomas. A novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.

Wilfred D. Stein<sup>1,2</sup>







James Yang<sup>3</sup>

Susan E. Bates<sup>1</sup>

Tito Fojo<sup>1,4</sup>

# Patients Randomized to Placebo







Tumor quantity (Starting quantity arbitrarily set at 100%)



Weeks on study

# Patients Randomized to Placebo







Tumor quantity (Starting quantity arbitrarily set at 100%)



Weeks on study

# Patients Randomized to Placebo


Tumor quantity (Starting quantity arbitrarily set at 100%)




Weeks on study

# Patients Randomized to Placebo


Tumor quantity (Starting quantity arbitrarily set at 100%)




27




28




29



30



31









32

Weeks on study

# Patients Randomized to Placebo

Tumor quantity (Starting quantity arbitrarily set at 100%)



Weeks on study